Publications by authors named "Hiroshi Tsuge"
Article Synopsis
- Pembrolizumab, an immune checkpoint inhibitor, shows effectiveness in treating recurrent and metastatic salivary gland carcinoma (SGC), but no predictive biomarkers for its efficacy have been established prior to this study.
- A study involving 27 patients identified optimal cut-off values for the combined positive score (CPS) and tumor proportion score (TPS) of PD-L1, which were found to significantly predict treatment outcomes.
- The overall response rate for SGC was 25.9%, with higher response rates in patients with high CPS and TPS, and a lower platelet-lymphocyte ratio correlated with improved progression-free survival, while the treatment demonstrated a good safety profile with no severe adverse events.
Article Synopsis
- A large study analyzed data from 444,143 Japanese individuals to investigate the relationship between body mass index (BMI) and lung cancer risk.
- Results showed that lower BMI, specifically under 18.5, increased lung cancer risk, while being overweight or obese correlated with reduced risk.
- The findings suggest an inverse relationship between BMI and lung cancer risk in the Japanese population, with the effect being more significant in male smokers, indicating possible smoking-related confounding.
Background: It is unclear witch regimen is optimal as salvage chemotherapy (SCT) after immune checkpoint inhibitor (ICI) monotherapy for recurrent or metastatic head and neck cancer (RM-HNC).
Methods: This study enrolled 109 patients. Overall survival (OS) and progression-free survival 2 (PFS2) were compared between patients stratified by SCT regimen.
Advances in diagnostic techniques and treatment modalities have impacted head and neck cancer (HNC) prognosis, but their effects on subsite-specific prognosis remain unclear. This study aimed to assess subsite-specific trends in mid- and long-term survival for HNC patients diagnosed from 1993 to 2011 using data from population-based cancer registries in Japan. We estimated the net survival (NS) for HNC by subsite using data from 13 prefectural population-based cancer registries in Japan.
View Article and Find Full Text PDFImmune checkpoint inhibitors (ICIs) have become the standard treatment for recurrent or metastatic head and neck cancer (RM-HNC). However, many patients fail to benefit from the treatment. Previous studies have revealed that tumor burden predicts the efficacy of ICIs, but this association remains unclear for RM-HNC.
View Article and Find Full Text PDFAlthough several prognostic factors in nivolumab therapy have been reported in recurrent or metastatic head and neck cancer (RM-HNC) patients, these factors remain controversial. Here, we conducted a multicenter retrospective cohort study to investigate the impact of clinico-hematological factors on survival in RM-HNC patients treated with nivolumab. We reviewed 126 RM-HNC patients from seven institutes.
View Article and Find Full Text PDFPrimary squamous cell carcinoma of the thyroid (PSCCT) is a rare disease with a poor prognosis. Because of its rarity, there is no established therapeutic regimen in unresectable cases. We report a case of PSCCT treated with weekly paclitaxel (wPTX) for more than 2 years.
View Article and Find Full Text PDF